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T cell mediated adoptive immune response has been characterized as the key to anti-tumor immunity. Scientists around the 
world including in China, have been trying to harness the power of T cells against tumors for decades. Recently, the biosyn-
thetic chimeric antigen receptor engineered T cell (CAR-T) strategy was developed and exhibited encouraging clinical efficacy, 
especially in hematological malignancies. Chimeric antigen receptor research reports began in 2009 in China according to our 
PubMed search results. Clinical trials have been ongoing in China since 2013 according to the trial registrations on clinicaltri-
als.gov.. After years of assiduous efforts, research and clinical scientists in China have made their own achievements in the 
CAR-T therapy field. In this review, we aim to highlight CAR-T research and clinical trials in China, to provide an informative 
reference for colleagues in the field. 
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In recent years, chimeric antigen receptor engineered T cell 
(CAR-T) therapy emerged as a leading role in the cancer 
immunotherapy arena (Yang, 2015). The excitement sur-
rounding CAR-T therapy is kindled by thrilling objective 
results from clinical trials, owing to years of diligent col-
laborative study from laboratory and clinical scientists. 
CAR-T was originally proposed by Zelig Eshhar and col-
leagues working at the Weissman Institute in Israel 27 years 
ago (Gross et al., 1989). CAR-T combines the recognition 
advantage of the scFv (single chain fragment variable) from 
monoclonal antibodies and the tumor lysis ability of indi-
vidual T cells, which enables engineered T cells to target 
and kill tumor cells. This MHC (major histocompatibility 
complex)-independent strategy makes MHC down- 
regulated tumor cells no longer “invisible” to T cells, and 
enables the direct triggering of effector functions by CAR 
molecules (Chmielewski et al., 2013; Oren et al., 2014). 
Research and clinical trials focusing on CAR-T therapy are 
in progress worldwide, including in China. According to 
registrations on clinicaltrials.gov., there are 94 CAR-T cell 
therapy studies worldwide. China has the second most 
on-going clinical trials (26 studies) at present. Academic 
institutions, hospitals, and enterprises in China have 
launched multiple CAR-T associated studies, with promis-
ing outcomes being reported in the past few years. Although 
in its infancy, CAR-T therapy in China is thriving on chal-
lenges and opportunities. In this review, we have summa-
rized the past CAR-T research and clinical trials, and looked 
into the future of CAR-T therapy in China. 
CAR CONSTRUCTS 
CAR constructs are mainly composed of four elements,  
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including antigen-recognizing scFv, the spacer and 
trans-membrane domain, the co-stimulatory domain and the 
signaling domain (Sadelain et al., 2013). 
The most used scFvs in China are derived from well de-
scribed antibodies, such as anti-CD19 scFv from FMC63 
(Dai et al., 2015) and anti-CD20 scFv from HB-9645 
(Wang et al., 2014) etc. (Table 1). The use of these scFv 
fragments to target the well recognized tumor associate an-
tigens partially assure the specificity and safety, which is 
preferable for clinical trials. Due to the limited number of 
antigens for tumor cell targeting, some original scFv frag-
ments targeting potential tumor associate antigens have also 
been developed in China, such as anti-LMP1 (Epstein-Barr 
virus (EBV) latent membrane protein 1) scFv for 
EBV-positive cancer cells (Tang et al., 2014) and anti- 
CMA1 scFv for chronic myeloid leukemia cells (Wang et al., 
2012) (Table 1). Most of the scFv sequences are derived 
from mouse monoclonal antibodies. To avoid potential im-
munogenicity, humanized antibodies and human antibodies 
are being developed (Wang et al., 2012). The strategy of 
using scFv sequences from the patients’ auto-antibodies is 
proposed to circumvent immunogenicity (Weibo and 
Zhaoming, 2012). To improve the scFv fragments, scientists 
abroad screened the affinity of scFvs to control the “on tar-
get-off tumor” effect. With respect to the same antigen, low 
affinity scFvs binding tumor cells rather than healthy tissue 
are preferred (Cruz, 2014; Zhao et al., 2015). However, 
given the present technology and the limited human tissue 
samples, clinical trials are essential for the confirmation of 
the safety of a given scFv targeting a given antigen.  
The usage of the spacer and trans-membrane domains of 
CARs are quite empirical; the former mostly depend on the 
targeting epitope of the specific scFv, while the structural 
and biochemical impact of the latter remains largely  
unknown. The spacers used in China are mainly CH2CH3, 
Fc hinge, and CD8 hinge (Deng et al., 2015; Guo et al., 
2015; Wang et al., 2013) (Table 1). Recently, it has been 
reported that CH2CH3 spacer could bind soluble 
Fc-receptors and cause off-target cell lysis (Almåsbak et al., 
2015), and that the mutation or deletion of the CH2 region 
could obviate this problem. Previous studies showed that 
the distance of the target epitope from the cell membrane is 
an important parameter for the design of a spacer. For 
epitopes proximal to membrane such as CD22, a longer 
spacer is better; while for other epitopes such as receptor 
tyrosine kinase-like orphan receptor 1 (ROR1), shorter 
spacers are preferred (Hudecek et al., 2013; Turtle, 2013). 
These studies indicate that, to promote the efficiency of 
CARs, the spacer domain needs to be tailored for each of 
the different target molecules. The trans-membrane do-
mains used in China are mainly derived from CD28 and 
CD8 (Wang et al., 2014; Zhou et al., 2013). Although 
comparative results are not yet available, it is presumable 
that the trans-membrane domains in favor of CAR-based 
immune synapse formation might be more advantageous. 
The co-stimulatory domains used in China are mainly 
CD28, CD137 and inducible costimulate (ICOS) (Gao et al., 
2014; Guo et al., 2015; Zheng et al., 2010) (Table 1). CD28 
and ICOS are B7 family members, while CD137 is a mem-
ber of the tumor necrosis factor receptor (TNFR) family. 
CD28 co-stimulation is essential for naive T cells, and 
ICOS and CD137 are expressed following the induction of 
CD28 signaling (Curran et al., 2012). CD28 is superior for 
IL-2 production, and clonal expansion of CAR-T cells. 
ICOS can help T cells polarize into TH17/TH1 cells and 
enhance tumor cell lysis capacity (Finney et al., 2003). 
CD137 specifically reprogram T cells for multifunctional cyto-
kine secretion and enhanced persistence (Carpenito et al., 
2009; Song et al., 2011). CD137 also ameliorates T cell 
exhaustion induced by the spontaneous signaling of CARs 
(Long et al., 2015; van der Stegen et al., 2015). Other po-
tential molecules such as OX40 and CD27 are also being 
used as co-stimulatory domains. OX40 can repress IL-10 
secretion and counteract the self-repression of activated T 
cells (Hombach et al., 2012). CD27 is able to enhance ef-
fector function and proliferation, and mediate greater per-
sistence as compared with CD28 (Song et al., 2012). It is 
generally agreed that second-generation CARs are more 
effective than those of the first-generation, but there is no 
agreement on which co-stimulatory molecule is the best or 
whether third-generation CARs are superior (Turtle, 2014). 
This is probably due to the use of different scFvs, different 
tumor models, different expression systems and different 
CAR expression levels in each laboratory. For each CAR 
construct, comparisons of the co-stimulatory molecules in 
vitro and in vivo are still needed to define the most suitable 
co-stimulatory domain. The signaling domains used in Chi-
na are all CD3. CD3 is mainly used as the signaling do-
main worldwide, while FcRI is less used (Srivastava and 
Riddell, 2015). Moreover, it is also reported that CD3- 
conducts superior signaling efficacy of CARs as compared 
to FcRI (Haynes et al., 2001). 
In general, the CAR constructs in China are mainly sec-
ond-generation CARs that synchronize with their global 
counterparts. In addition to the three generations of CARs, 
the fourth-generation CARs or “TRUCKs” have been de-
veloped abroad (Chmielewski and Abken, 2015). These 
new CARs endow T cells with additional cytokine produc-
tion such as IL-12 (Chmielewski et al., 2011) or IL-15 
(Hoyos et al., 2010). Also, other modifications are also in-
troduced into CAR-T cells, such as CD137 co-stimulatory 
ligand expression (Zhao et al., 2015), bi-specific antigen 
recognition targeting prostate specific membrane antigen 
(PSMA) and prostate stem cell antigen (PSCA) (Kloss et al., 
2013), and extracelluar matrix degradation with heparanase 
(Caruana et al., 2015) etc.. Recently, an on-switch CAR 
paradigm was also developed, which allowed the activation of 
CAR-T cells to be controlled by small molecules (Wu et al., 
2015). Although the next generation strategies help to im-
prove the function of CAR-T cells, they also increase the 
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Table 1  Published Results on CAR-T therapy in Chinaa) 
Antigen Tumor target Sponsor Receptor Culture 
Gene 
transfer Model Date
CD123 Acute myeloid 
leukemia 
Anhui Provincial Hospital; Baylor 




CD138 Multiple myeloma Chinese PLA General Hospital scfv-CD8a hinge and 
TM-CD137-CD3zeta 
CD3+IFN-r+IL-2 Lentivirus Human 2014
CD19 B-cell lineage 
acute lymphocytic 
leukemia 
Chinese PLA General Hospital scfv-CD8a hinge and 
TM-CD137-CD3zeta 




large B cell lym-
phoma 
Chinese PLA General Hospital scfv-CD8a hinge and 
TM-CD137-CD3zeta 
CD3+IFN-r+IL-2 Lentivirus Human 2014
CD20 B-cell lymohoma The First Affiliated Hospital of 




CD33 Acute myeloid 
leukemia 
Chinese PLA General Hospital scfv-CD8a hinge and 
TM-CD137-CD3zeta 
CD3+IFN-r+IL-2 Lentivirus Human 2015









EGFR EGFR positive 
malignancies 
Huaihe Hospital of Henan Univer-
sity 







EGFRvIII Glioma Peking University avidin-CD8-CD28-TNFRSF9-
CD3zeta 
CD3+CD28+IL-2 Lentivirus BALB/c 
nude mice 
2015
EGFRvIII Glioma Zhengzhou University People’s 
Hospital 





Peking Union Medical College and 














ErbB2 Breast cancer Wenzhou Medical College scFv-Fc-CD28-CD3 PHA-L+CD3+IL-2 Electro-
poration 
Vitro 2012












Shandong Cancer Hospital and 
Institute 
NKG2D-CD28-CD3zeta CD3+CD28 Lentivirus Vitro 2015
GPC3 Hepatocellular 
carcinoma 










Nanjing Medical University scfv-IgG1CH2CH3-CD28-CD
3zeta 















a) The published results are collected from PubMed search results with combinations including “chimeric antigen receptor” and “CAR-T cells”, and the 
results are collected before 15th January 2016. Due to the limited collection approach, the results might not be comprehensive, please understand if there are 
any omissions. 
difficulty of gene modification, and the safety and efficacy 
of these newly developed constructs have yet to be estab-
lished in human studies (Chmielewski and Abken, 2015). In 
China, the next-generation CARs are also being developed 
at present, and hopefully, they will help improve the safety 
and efficacy of CARs, thus taking Chinese CARs to the 
next level. 
CAR-T CELL CULTURE AND ENGINEERING 
In China, T cells used for CAR modification are acquired 
from peripheral blood mononuclear cell (PBMC) culture. 
To activate T cells, combination such as OKT3+CD28, 
OKT3+ interferon gamma (IFN- or phytohemagglutinin 
(PHA)-L+IL-2 are used for days of stimulation, after which, 
the cells are maintained with IL-2 (Table 1). The whole 
culture process lasts about 10–14 d (Gao et al., 2014;  
Wang et al., 2014, 2015). The stimulation process aims to 
make T cells susceptible to viral transduction, especially 
retrovirus, and to achieve a large number of T cells. T cells 
infused back to patients are expanded about 100–1,000 fold 
in vitro, which tend to induce T cell terminal differentiation. 
Preclinical studies abroad showed that the adoptive transfer 
of T cells with the less differentiated naïve and central 
memory phenotype have greater persistence and antitumor 
effects than the transfer of terminally differentiated effector 
cells (Gattinoni et al., 2005, 2011; Hinrichs et al., 2011). To 
achieve the less differentiated cells, one approach is to iso-
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late the TN (Naïve T) or TCM (central memory T) cells 
(Wang et al., 2012), while the other approach is to optimize 
the culture condition to accommodate the less differentiated 
cells. Recently, -chain cytokines including IL-7, IL-15, and 
IL-21 have been shown to better preserve the naive and 
central memory phenotype of T cells compared to IL-2 
(Perna et al., 2014; Singh et al., 2011; Xu et al., 2014). The 
usage of these cytokines could be in favor of the T cell cul-
ture in China. Additionally, because the less differentiated T 
cells have greater proliferative potential and tumoricidal 
capacity in vivo, the culture time and transfer dose of T cells 
might be reduced. This will simplify the practicalities of 
CAR-T cell production and hopefully improve the whole 
delivery system. 
The gene modification methods of CAR-T cells in China 
are mainly lentivirus (Wang et al., 2015), retrovirus trans-
duction (Deng et al., 2015) and plasmid electro-transfection 
(Wang et al., 2013) (Table 1). Virus transduction is favora-
ble for inserting the gene of interest into the target cell ge-
nome and precipitating continuous expression. While plas-
mid transfection enables the transient expression of genes, 
stable expression can be achieved through additive antibi-
otic screening. The virus system is more advantageous for 
creating stable CAR expressing T cell and prolonging CAR 
expressing T cells in vivo. Although there is a remote possi-
bility that retrovirus or lentivirus conducted gene insertion 
could induce oncogenic-associated mutations, evidences 
from clinical studies till now indicate that this approach is 
generally safe (Barrett et al., 2014; Gill and June, 2015). 
Moreover, transposon systems such as sleeping beauty 
(Deniger et al., 2015; Singh et al., 2015) and piggybac 
(Nakazawa et al., 2011; Ramanayake et al., 2015) have been 
explored for CAR modification and used in hematological 
malignancy therapies abroad, the clinical safety and efficacy 
of which are under evaluation. The temporary expression of 
CAR conducted by recently developed mRNA transfection 
is also accepted because it will not cause insertional muta-
genesis. Also, the limited expression time is preferable for 
CARs targeting antigens with potential risk (Kenderian et al., 
2015; Krug et al., 2014). Theoretically, lentiviruses and 
transposons can transfect undivided cells, and thus avoid 
stimulation induced T cell differentiation; however, stimu-
lation with mitogenic agents is still needed to change the 
resistant state of primary T cells (Cheadle et al., 2014; 
Morgan and Kakarla, 2014). Besides, transcription activa-
tor-like effector nuclease (TALEN) system is used to knock 
out TCR and CD52, in order to achieve “off the shelf” 
CAR-T cells (Couzin-Frankel, 2015; Poirot et al., 2015). 
Other gene editing tools such as CRISPR/Cas9 are also be-
ing used to develop more favorable CAR-T phenotype. An 
approach that is able to efficiently transfect T cells without 
causing T cell differentiation is ideal. The present gene de-
livery systems may be satisfactory for mouse studies and 
clinical trials, but they are still expensive and difficult for 
steady large-scale production. In general, an optimal gene 
delivery system is crucial for the CAR industry and clinical 
efficacy, the improvement of which will promote the de-
velopment of the industry as a whole. Considering that 
CAR-T therapy is a personalized treatment strategy and that 
the engineering and transportation processes are crucial, it is 
necessary to build multiple regional clinical trial stations. 
Cooperation between multiple local research institutions 
and hospitals would help in the building of this CAR-T 
clinical trial network. 
CAR-T CELLS TARGETING 
HEMATOLOGICAL MALIGNANCIES 
CAR-T cells are used in treating hematological malignan-
cies including acute lymphocytic leukemia, chronic lym-
phocytic leukemia, lymphoma and multiple myeloma. The 
target antigens include CD19 (Dai et al., 2015), CD20 
(Wang et al., 2014), CD30, CD33 (Wang et al., 2015) and 
CD138 (Guo et al., 2015) (Table 2). CD19 is the most pop-
ular target in China, where clinical trials are being conduct-
ed in institutions including the Chinese PLA General Hos-
pital, Affiliated Hospital to Academy of Military Medical 
Sciences and The Second Hospital of Anhui Medical Uni-
versity etc.. According to PubMed search results, the pub-
lished clinical data in China are mainly from the Chinese 
PLA General Hospital. To date, three clinical studies have 
been reported. In a pilot clinical trial, autologous or do-
nor-derived T cells modified to express CAR19 were used 
to treat patients with relapsed or chemotherapy-refractory 
B-cell lineage acute lymphocytic leukemia (B-ALL). Nine 
patients were enrolled, six of whom had extramedullary 
involvement. Five patients had objective hematopoietic 
system and extramedullary tissue response for 2–9 months. 
Cytokine release syndrome (CRS) was observed in most 
cases. In two patients who received donor-derived cells, 
grade 2–3 graft-versus-host disease (GVHD) was observed 
(Dai et al., 2015). Moreover, patients with chemotherapy 
refractory advanced diffuse large B cell lymphomas 
(DLBCL) were treated with CAR20 T cells. Two patients 
with no bulky tumors were enrolled, and one achieved a 
durable complete remission for 14 months while the other 
achieved a 6-month regression. Five patients with bulky 
tumor burdens were also treated, and three of them achieved 
tumor regressions lasting 3–6 months. The associated toxic-
ities mainly included cytokine release syndrome, tumor lysis 
syndrome, alimentary tract hemorrhage and intrapulmonary 
inflammation surrounding extranodal lesions (Wang et al., 
2014). Also, one patient with acute myeloid leukemia 
(AML) was treated with CAR33 T cells. A marked decrease 
of blasts in the bone marrow was observed two weeks after 
therapy, and there was a gradual increase until disease pro-
gression occurred nine weeks after therapy. Cytokine re-
lease syndrome was also observed in the patient (Wang et al., 
2015). In these studies, it was observed that CAR-T cells 
reached their peak 2–3 weeks after cell infusion, and this 
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Table 2  Clinical trials in China infusing CAR-T cellsa) 
Antigen Tumor target Sponsor Phase 
Number 




Liver cancer; Pancreatic cancer; Brain 
tumor; Breast cancer; Ovarian tumor; 
Colorectal cancer; Acute myeloid and 
lymphoid leukemias 
Chinese PLA General Hospital Phase 1 20 NCT02541370 2015 
CD138 
Relapsed and/or chemotherapy resistant 
multiple myeloma Chinese PLA General Hospital Phase 1 / Phase 2 10 NCT01886976 2013 
CD19 Acute lymphoblastic leukemia 
Affiliated Hospital to Academy of 
Military Medical Sciences; Peking 
University 
Phase 1 5 NCT02186860 2015 
CD19 Non-hodgkin lymphoma; Mantle cell 
lymphoma 
Chinese PLA General Hospital Phase 1 / Phase 2 2 NCT02081937 2014 
CD19 
Relapsed and/or chemotherapy refractory 
B-cell malignancy 
Chinese PLA General Hospital Phase 1 12 NCT01864889 2013 
CD19 B-cell lymphomas 
Peking University; University of 
Florida Phase 1 / Phase 2 20 NCT02247609 2014 
CD19 Relapsed/refractory leukemia and lym-
phoma 
Shanghai Tongji Hospital, Tongji 
University School of Medicine 
Phase 1 / Phase 2 40 NCT02537977 2015 
CD19 
Chronic lymphocytic leukemia; Acute 
lymphocytic leukemia; Lymphoma 
Shenzhen Second People’s Hospital; 
Shenzhen institute for innovation and 
translational medicine 
Phase 1 36 NCT02456350 2015 
CD19 Leukemia; Lymphoma Southwest Hospital Phase 1 45 NCT02349698 2014 
CD19 Recurrent or refractory B-cell tumor Second Military Medical University Phase 1 / Phase 2 20 NCT02644655 2015 
CD19 Leukemia; Lymphoma Beijing Doing Biomedical Co., Ltd.; 
First Hospital of Jilin University 
Phase 1 100 NCT02546739 2016 
CD19 
Recurrent or stage III/IV diffuse large cell 
lymphoma; Follicular lymphoma; Mantle 
cell lymphoma 
Xinqiao Hospital of Chongqing Phase 1 / Phase 2 20 NCT02652910 2015 
CD30 
Hodgkin’s lymphoma; Non-Hodgkin’s 
lymphoma Chinese PLA General Hospital Phase 1 / Phase 2 30 NCT02259556 2014 
CD30 Lymphomas Peking University; University of 
Florida 
Phase 1 / Phase 2 20 NCT02274584 2014 
CD33 
Relapsed and/or chemotherapy refractory 
adult myeloid leukemia 
Chinese PLA General Hospital Phase 1 / Phase 2 10 NCT01864902 2013 
CEA 
Lung cancer; Colorectal cancer; Gastric 
cancer; Breast cancer; Pancreatic cancer Southwest Hospital Phase 1 75 NCT02349724 2014 
EGFR Advanced EGFR-positive solid tumors Chinese PLA General Hospital Phase 1 / Phase 2 10 NCT01869166 2013 
EGFR Advanced glioma RenJi Hospital Phase 1 10 NCT02331693 2014 
EphA2 EphA2 positive malignant glioma Fuda Cancer Hospital Phase 1 / Phase 2 60 NCT02575261 2015 
GPC3 Hepatocellular carcinoma RenJi Hospital Phase 1 10 NCT02395250 2015 
HER-2 
Chemotherapy and/or  HER-2 antibody 
inhibitor therapy refractory advanced 
HER-2 positive solid tumors 
Chinese PLA General Hospital Phase 1 / Phase 2 10 NCT01935843 2013 
HER-2 Breast cancer Fuda Cancer Hospital Phase 1 / Phase 2 60 NCT02547961 2015 
Meso-
thelin 
Malignant mesothelioma; Pancreatic can-
cer; Ovarian tumor; Triple negative breast 
cancer; Endometrial cancer; Other meso-
thelin positive tumors 
Chinese PLA General Hospital Phase 1 20 NCT02580747 2015 
MUC1 
Malignant glioma of brain; Colorectal 
carcinoma; Gastric carcinoma 
PersonGen Biomedicine (Suzhou) Co., 
Ltd.; Anhui General Hospital of 
Armed Police Forces 
Phase 1 / Phase 2 20 NCT02617134 2015 
a) The clinical trials are collected from clinicaltrial.gov., search results with combinations including “chimeric antigen receptor” and “CAR-T cells”, and 
the results are collected before 15th January 2016. Due to the limited collection approach, the results might not be comprehensive, please understand if there 
are any ommissions. 
was maintained for a couple of months. Broadly speaking, 
these clinical results are highly inspiring with multiple re-
ports of objective clinical responses in patients with ad-
vanced, chemo-refractory hematological malignancies 
treated with CAR modified T cells.  
Some clinical issues are also addressed in these studies. 
Preconditioning therapy has been shown to enhance the 
efficacy of CAR-T therapies. On one hand, the lympho-  
depletion treatments could induce the clearance of Tregs 
and help the expansion of infused T cells in a lymphocyte 
homeostatic fashion (Rosenberg and Restifo, 2015). On the 
other hand, the de-bulking treatments could reduce the tu-
mor burden and disrupt the tumor structure, thus enhancing 
the trafficking of T cells and mitigating tumor lysis syn-
dromes (Lee et al., 2014). Toxicities including cytokine 
release syndrome, tumor lysis syndrome, neural toxicity and 
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inflammation accompany with clinical efficiencies. To en-
sure the safety of CAR-T cell transfusion, the cell doses are 
used in an escalating manner. Etanercept (anti-TNFa), to-
cilizumab (anti-IL-6R) or corticosteroids are used for con-
trolling cytokine release syndromes (Wang et al., 2014). 
Organ distribution is decisive for CAR-T cells to interact 
with tumor cells. It is reported that CAR copies can be de-
tected in the bone marrow, cerebrospinal fluid and nodules, 
but cannot be detected in adipose and extramedullary tis-
sues. The distribution patterns of CAR-T cells provide an 
explanation for the different clinical responses after cell 
infusions. Furthermore, donor-derived T cells can cause 
GVHD (graft-versus-host disease) for some patients, indi-
cating that CAR-T cells should be used with caution for 
patients who have received allogeneic hematopoietic stem 
cell transplantation (allo-HSCT) (Dai et al., 2015). For these 
patients, EBV specific T cells (Pule et al., 2008; Terakura et al., 
2012) or TCR-knocked out CAR-T cells (Poirot et al., 
2015) are possible solutions. EBV specific T cells or 
TCR-deficient T cells are not able to recognize host an-
tigens, and thus, the attack of host tissues can be avoided 
(Cruz et al., 2013; Poirot et al., 2015; Valton et al., 2015). 
Generally speaking, hematological malignancies are 
most responsive to CAR-T therapy so far. Inspiring results 
of CAR-T-19 therapy from the Memorial Sloan Kettering 
Cancer Center (Davila et al., 2014), the National Cancer 
Institute (Lee et al., 2015) and the University of Pennsylva-
nia (Maude et al., 2014) have been reported. In accordance 
with studies in China, they have all reported the feasibility 
and anti-tumor efficacy of CAR-T cells against hematolog-
ical tumors. According to the data reported, complete re-
mission (CR) rates in China are not as high as in the US 
(Maude et al., 2015). The patients’ background largely ac-
counts for this difference. In China, the participants recruit-
ed in clinical trials are often more heavily treated and in 
their later stages as compared to the participants in the US. 
Clinicians in China would largely improve this situation if 
they would encourage patients relapsed or refractory from 
standard treatments to participate in reliable clinical trials.  
There are some attributes of hematological malignancies 
that make them suitable targets for CAR-T therapy. In he-
matological malignancies, the tumor cells are in the circula-
tion system, which makes them easier for T cells to inter-
cept and more accessible for evaluation (Porter et al., 2015). 
Tumor-specific antigen expression is relatively limited. For 
example, CD19 is restrictedly expressed by B cells, which 
is favorable for avoiding on target-off tumor toxicity. Since 
the target cells are in the circulation system, the infused T 
cells can be directly activated by the antigens and main-
tained in the system for immune surveillance. Hematologi-
cal tumor cells always express co-stimulatory molecules, 
whereas solid tumor cells usually lack such molecules 
(Maude et al., 2015; Sadelain, 2015; Turtle, 2014). With 
these advantageous features for CAR-T therapy, the clinical 
outcomes of hematological malignancies are quite encour-
aging. In contrast, due to their lack of natural favorable 
characteristics, non-hematological malignancies remain as 
challenging targets for CAR-T therapy. 
CAR-T CELLS TARGETING 
NON-HEMATOLOGICAL MALIGNANCIES 
AND COMBINATORIAL STRATEGIES 
In contrast to the success observed in the treatment of he-
matological malignancies, there is a lack of encouraging 
clinical data about CAR-T therapy for solid tumors. In Chi-
na, according to published results, T cells are modified with 
CARs targeting EpCAM (epithelial cell adhesion molecule) 
for prostate cancer (Dai et al, 2015), EGFRvIII (epidermal 
growth factor receptor variant III) for glioma (Liu et al., 
2015; Shen et al., 2013), LMP1 for nasopharyngeal cancer 
(Tang et al., 2014), GPC-3 (glypican-3) for hepatocellular 
carcinoma (Gao et al., 2014), and VEGFR-1 (vascular en-
dothelial growth factor receptor 1) (Gao et al., 2015) and 
EGFR (Zhou et al., 2013) for multiple tumors (Table 1). 
These preclinical studies have shown potential and have 
paved the way for the evaluation of CARs in clinical set-
tings. According to the clinical trial registrations, CARs 
targeting EGFR, Her-2 (human epidermal growth factor 
receptor-2), EGFRvIII and GPC-3 for multiple solid tumors 
are under investigation (Table 2). To improve the efficacy 
of CARs in targeting non-hematological malignancies, there 
are some issues that need to be addressed. 
Tumor antigens used as CAR targets mainly include mu-
tated antigens, lineage antigens and over-expressed anti-
gens. In hematological malignancies, especially B cell ma-
lignancies, the most successful target antigen CD19 is line-
age restricted. The targeting of such a lineage limited anti-
gen is relatively safe, and its eradication can lead to conse-
quences that are remediable (Maude et al., 2015; Sadelain, 
2015). For solid tumors, mutated antigens are attractive tar-
gets. EGFRvIII is the most common variant of EGFR ob-
served in human tumors, and particularly in glioblastoma. 
CARs targeting EGFRvIII have been developed for glio-
blastoma, after the demonstration of safety and efficacy in mouse 
models, phase I clinical trial is underway (Johnson et al., 2015; 
Morgan et al., 2012). Mutated antigens and lineage antigens 
are favorable but rare, and most of the available antigens are 
over-expressed antigens such as EGFR, Her-2 and GPC-3. 
These antigens expressed in tumor cells are also expressed 
in normal cells at lower level. This makes the on target-off 
tumor toxicity a critical issue (Hinrichs and Restifo, 2013; 
Kakarla and Gottschalk, 2014; Song et al., 2015). ScFv af-
finity optimization is helpful for solving this problem 
(Caruso et al., 2015; Liu et al., 2015). The future develop-
ment of CARs targeting solid tumor antigens in China may 
also benefit from scFv affinity optimization. Moreover, the 
safety switch iCaspase 9 (Budde et al., 2013) and iCAR 
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strategy (Fedorov et al., 2013) also have potential to divert 
off-target immune responses. 
Effective CAR-T therapy requires not only the genera-
tion of cancer-specific T cells, but also that these T cells can 
physically contact cancer cells directly. Solid tumors are 
known to be comprised of abundant extracellular matrix and 
tumor-associated stroma cells. The structure and microen-
vironment of solid tumors makes them privileged for T cell 
exclusion. Such a circumstance makes T cell traffic a her-
culean hurdle for CAR-T therapy in solid tumors (Joyce and 
Fearon, 2015). To improve the trafficking of adoptive 
transferred T cells, some approaches have been developed 
abroad in recent years. Prasad et al. compared conventional 
systemic intravenous and regional intra-pleural administra-
tion for the treatment of malignant pleural mesothelioma. 
They found that intra-pleural T cell administration was su-
perior against pleural disease and even disseminated tumor 
sites (Adusumilli et al., 2014). For solid tumors residing in 
elastic cavities, this regional administration approach may 
be an advantageous option. T cell traffic in the tumor blood 
vessel requires the interaction between chemokines and 
chemokine receptors (CCR) (Molon et al., 2011). Edmund 
et al. found that CAR-T cells with chemokine receptor ex-
pression had superior tumor localization and antitumor ef-
ficacy as compared with conventional CAR-T cells (Moon 
et al., 2011). Thus, for the treatment of tumors secreting an 
abundance of certain types of chemokines, the modification 
of CAR-T cells to express matched CCRs is beneficial. 
Once T cells enter the tumor mass, extracellular matrix 
(ECM) in stroma-rich solid tumors forms another defense 
against T cell attacks. To ensure the continuous contact of T 
cells and tumor cells, T cells must be able to degrade ECM 
(Tan et al., 2015). Ignazio et al. engineered CAR-T cells to 
constitutively express heparanase, an enzyme that is able to 
degrade heparan sulfate proteoglycans, which are the pri-
mary components of ECM. Heparanase significantly pro-
motes tumor infiltration and the antitumor activities of 
CAR-T cells (Caruana et al., 2015). This study provided a 
potential approach that may enhance the efficiency of 
CAR-T cells, especially in stroma-rich solid tumors. The 
strategies above may help improve CAR-T cell structure in 
China, but they also need to be used with caution to prevent 
potential off-tumor toxicities.  
When CAR-T cells enter the tumor mass, they confront 
with multiple immune suppressive factors, including hy-
poxia, low pH, the lack of metabolic components, tu-
mor-derived cytokines or metabolites, immune suppressor 
cells, and inhibitory receptors (Beavis et al., 2015; Gajewski 
et al., 2013). Though co-stimulatory molecules such as 
CD28 and CD137 can maintain the survival of CAR-T cells, 
they do not sufficiently protect CAR-T cells from the inhi-
bition induced by the tumor microenvironment. It is report-
ed that CAR-T cell hypofunction was reversible when the 
cells were isolated from the tumor. Multiple factors contrib-
ute to the hypofunction of T cells, including intrinsic T cell 
inhibitory enzymes and the expression of surface inhibitory 
receptors (PD-1, LAG3, TIM3, and 2B4) (Beavis et al., 
2015; Enblad et al., 2015; Moon et al., 2014). The intercep-
tion of immune suppressive factors such as indoleamine 
2,3-dioxygenase (IDO) and PD-1 is proved to enhance the 
antitumor activity of CAR-T cells (John et al., 2013; 
Ninomiya et al., 2015). Inhibition of Akt signaling is also 
proven to promote the generation of superior tumor-reactive 
T cells by studies in China and abroad (van der Waart et al., 
2014, 2015; Wu et al., 2015). Except for these combinatori-
al therapies aimed at counteracting immune suppressive 
effects, other promising combinatorial strategies have also 
been evaluated. Epigenetic modifiers, capable of 
up-regulating tumor antigen expression and increasing tu-
mor antigen intensity, are beneficial for the eradication of 
tumor cells by CAR-T cells (Anurathapan et al., 2014). 
Whole Cell vaccine is also reported to enhance antitumor 
responses of CAR-redirected cytotoxic T lymphocytes re-
cently (Caruana et al., 2015). Chemotherapy is already used 
as pre-conditioning therapy in hematological malignancies. 
For solid tumors, chemotherapy and other tumor cytotoxic 
agents are able to change the tumor structure by inducing 
tumor cell death, affecting tumor stromal cells, and even 
reducing myeloid-derived suppressor cells (MDSCs) 
(Mahoney et al., 2015). These changes in the tumor micro-
environment induced by tumor cytotoxic agents suggest it 
as a synergistic companion for CAR-T therapy. Additional-
ly, new combinations of CAR-T therapy and other current 
approaches including radiotherapies and antibodies target-
ing tumor cells also require further exploration. 
FINAL THOUGHTS 
CAR-T therapy has brought a new hope to cancer patients 
around the world, including China. However, there are still 
issues to be solved for CAR-T cell application, including 
side effects such as on target-off tumor effect, CRS and 
neural toxicity, optimal cell dosage and infusion frequency, 
enhancement of specificity and efficacy for solid tumors, 
and recurrence and treatment post CAR-T therapy. Adop-
tive immune cell therapy is categorized as one of the third 
kind medical technologies in China. A notice was released 
by the National Health and Family Planning Commission of 
PRC (NHFPC) on June 29th, 2015. This notice declares the 
cancelation of the approval procedure of the third kind 
medical technologies clinical application in China, and in its 
place, a registration system has been adopted. Medical or-
ganizations are responsible for the clinical application of the 
third kind medical technologies themselves. This notice 
made CAR-T therapy more accessible to general medical 
organizations; however, due to its potential side effects and 
toxicities, the clinical application of CAR-T cells should be 
pursued with caution. Since the understanding of CAR-T 
therapy is limited so far, large-scale general hospitals with 
both medical and research orientations are favorable to the 
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clinical application and development of CAR-T therapy. 
Since the process of CAR-T therapy involves both cell pro-
cessing approaches and gene modification products, it is 
presumable that the approval of this therapy would require 
the certification of both in the future. For the future indus-
trialization of CAR-T therapy, the cooperation of enterpris-
es and medical organizations will be helpful. In the US, 
Juno cooperates with the University of Pennsylvania Medi-
cal Center and Kite collaborates with National Cancer In-
stitute. In China, Cellular Biomedicine Group partners with 
the Chinese PLA General Hospital. It is estimated that 
CAR-T therapy would cost tens of thousands of RMB for 
one patient; therefore, large-scale clinical trials of CAR-T 
therapy would be in need of a large amount of financial 
support. Wall Street has already provided financial support 
for CAR-T therapy in the US (Barrett et al., 2015). Alt-
hough the use of CAR-T therapy is still in the early phases 
in China, we believe that the Chinese financial market will 
also lend a hand for CAR-T therapy in the near future. In 
recent years, basic researches aim to improve CAR-T effi-
cacy, safety, universality and applicability for treating solid 
tumors have made achievements in other nations world-
wide. Institutes or enterprises abroad have grown to be 
skilled in their particular areas. In China, though we have 
the second most CAR-T clinical trials for now, we are still 
in lack of self-dependent innovations so far. It is presumable 
that if “CARs” made in China want to go further, basic re-
search aim to understand and improve the present CAR is 
indispensable. To accelerate CAR-T therapy in China, we 
need to strengthen the independent research and develop-
ment of CAR-T cells, establish the safe and standard clini-
cal research systems, and actively carry out the relevant 
knowledge and application training of clinicians. The struc-
ture of CAR at present has achieved the recognition and 
stimulation of T cells. This has already exhibited surprising 
anti-tumor effects. We believe that the dis-inhibition of 
CAR-T cells and other combination strategies have great 
potential for promoting this therapy forward.  
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